Reviewed by the SwissAtlas coordination team · Last updated:
Maximum-privacy residential rehabilitation for CEOs, board chairs, and UHNW individuals requiring absolute institutional discretion
SwissAtlas operates exclusively as a non-medical coordination platform. We do not provide clinical services, diagnoses, or treatment recommendations. All medical decisions are made by licensed Swiss institutions following independent assessment.
For strategic context, review the private healthcare Switzerland institutional overview to understand governance, confidentiality standards, and non-clinical coordination boundaries across specialties.
Chief executive officers and equivalent senior leaders face unique challenges in seeking addiction treatment. The intersection of extreme professional responsibility, public visibility, fiduciary obligations, and personal vulnerability creates barriers to treatment that do not exist for most individuals. Concerns about board notification, shareholder disclosure, media exposure, professional reputation, and business continuity can delay or prevent treatment-seeking, allowing the condition to progress.
Treatment pathways for addiction in Switzerland are informed by guidelines published by the Federal Office of Public Health (OFSP) addiction guidelines and clinical standards from the Swiss Society of Addiction Medicine.
Swiss private rehabilitation institutions have decades of experience serving this specific population, developing treatment models that address these concerns systematically. The Swiss institutional framework — combining clinical excellence, absolute privacy protection, and a culture of discretion rooted in the country's private banking and wealth management traditions — provides an environment uniquely suited to CEO-level treatment.
Conditions commonly presenting in CEO populations include high-functioning alcohol dependence, stimulant use (cocaine, prescription amphetamines), prescription medication dependence (benzodiazepines, opioids), burnout and exhaustion syndromes, and behavioural addictions (gambling, compulsive risk-taking). Dual diagnosis with depression, anxiety, or trauma-related conditions is common.
SwissAtlas supports international families navigating complex medical situations with discretion and clarity. Each case is handled with strict confidentiality and a structured coordination approach. Designed for sensitive situations requiring discretion and clarity.
Families and senior professionals often delay first contact because confidentiality concerns, professional exposure, and institutional suitability are not always clear at the start. Some individuals are also uncertain how to proceed when treatment requires cross-border planning and formal admission sequencing. A structured Swiss pathway helps reduce ambiguity by organizing documentation, clarifying roles, and creating a controlled referral process under licensed institutional oversight. This allows decisions to be made calmly, discreetly, and within a defined governance framework.
CEO-level treatment in Switzerland operates within the highest tier of institutional privacy: single-occupant residential properties (private villas, alpine estates) where the client is the sole resident; dedicated clinical team assigned exclusively to the individual client; alias admission and registration protocols; private entrance, exit, and transport arrangements; encrypted communications and secure document handling; and no external identification of the property as a treatment facility.
CEO programmes operate at one-to-one or one-to-two therapy ratios, meaning the client receives substantially more individual therapeutic attention than in standard residential programmes. This includes daily individual psychotherapy, twice-weekly psychiatric review, personalised fitness and wellness programming, executive coaching integration, and comprehensive aftercare design.
Selected Swiss institutions accommodate limited continued professional engagement: private office space with secure connectivity, controlled communication windows, board liaison (through trusted intermediaries), and transition planning for extended absences. The clinical team balances therapeutic needs with the practical realities of executive responsibility.
Beyond the clinical framework, practical admission considerations often shape when and how families proceed with residential care planning.
CEO programmes typically range from four to eight weeks for primary treatment. The structured nature of one-to-one programming, private residential accommodation, and dedicated clinical team is reflected in costs that typically range from CHF 50,000 to CHF 150,000 per month. These are among the most exclusive and comprehensive addiction treatment programmes available globally. Swiss legal protections — FADP and Criminal Code Art. 321 — provide the highest level of privacy enforcement.
Pricing depends on clinical complexity, length of stay, institutional protocols, and accommodation level. All cost estimates are indicative and subject to individual clinical assessment by the treating institution. SwissAtlas does not determine or negotiate treatment fees.
Single-client residential treatment programmes operate under the same Swiss regulatory framework and clinical governance standards as larger institutions. Licensed Swiss medical directors — board-certified in psychiatry and addiction medicine — lead clinical teams comprising psychologists, psychotherapists, nursing staff, and allied health professionals. Treatment protocols follow the same evidence-based standards, with the distinguishing feature being the exclusively individualised delivery format.
Common co-occurring conditions (e.g., burnout syndrome, mood disorders, anxiety, post-traumatic stress, personality factors) may influence treatment planning; licensed clinicians evaluate these within integrated diagnostic frameworks. Clinical oversight and individualised assessment are led by Swiss licensed medical directors within partner institutions.
Addiction-related cases can affect high-functioning individuals with board, family, or reputational responsibilities. In that context, clarity of process is as important as confidentiality. SwissAtlas supports a calm and structured non-clinical pathway so administrative decisions, documentation flow, and admission logistics remain controlled from first intake to institutional handover.
This pathway may involve medically supervised assessment and treatment planning by licensed Swiss clinicians using recognized evidence-based standards. Specific protocol selection remains institution-dependent and is determined only after independent clinical evaluation.
From a coordination perspective, SwissAtlas focuses on clear admission sequencing, secure information flow, and administrative continuity. We do not define treatment protocols and do not intervene in clinical judgment.
Private treatment institutions in Switzerland operate under a dual regulatory architecture combining federal obligations and cantonal licensing oversight. All licensed institutions are required to comply with Swiss federal and cantonal regulation for patient safety, quality control, and operational accountability.
The Swiss Federal Act on Data Protection (FADP, revised 2023) sets strict requirements for processing and handling sensitive health information. In parallel, Swiss Criminal Code Article 321 enforces medical professional secrecy and establishes criminal sanctions for unauthorized disclosure of protected medical information.
Within this framework, SwissAtlas remains institutionally neutral. We do not provide clinical advice, do not recommend specific institutions, and do not influence medical decisions. Our role is limited to administrative access coordination, secure documentation handling, and international logistics support.
Governance-sensitive cases are often managed by family offices, board-level stakeholders, and legal advisors who require process clarity, controlled disclosure, and documented decision pathways. SwissAtlas structures the admission workflow to align with these governance requirements.
The coordination model emphasizes reputational risk mitigation through restricted-access communication, sequenced documentation flow, and role-based information governance. This structure supports institutional referral quality while minimizing unnecessary exposure of sensitive personal or corporate information.
For cross-border matters, SwissAtlas coordinates non-clinical timelines, document routing, and logistics so that institutional admission can proceed through a structured pathway consistent with private Swiss governance expectations.
Switzerland offers political neutrality, legal stability, and enforceable confidentiality protections that are highly relevant for governance-sensitive healthcare admissions. Its multilingual medical environment and established international reputation support structured cross-border coordination under a predictable institutional framework.
Private rehab for CEOs is positioned as a single-client format with exclusive staffing and dedicated operational infrastructure for one individual at a time. The value proposition is controlled exclusivity and maximal confidentiality rather than shared executive programming.
This model is intentionally separate from executive continuity pathways. It is selected when governance exposure and reputational sensitivity require a fully isolated treatment environment and a restricted stakeholder perimeter.
When a chief executive, board member, or senior partner enters a private treatment programme in Switzerland, the confidentiality framework extends well beyond clinical discretion. It intersects with Swiss criminal law, data protection legislation, securities obligations, and corporate governance structures that may require notification or disclosure under specific conditions. Families and advisors coordinating such admissions need to understand where legal protection begins, where it ends, and how coordination files can be structured to minimise legal exposure before the admission process starts.
Article 321 of the Swiss Criminal Code (CP) establishes professional secrecy obligations for physicians, therapists, and their auxiliary staff. Violation of this secrecy — even with the patient's implicit consent — carries criminal liability. This provision applies to all licensed healthcare professionals in Switzerland, regardless of whether the institution is private or public. For C-suite individuals, this means that treating physicians cannot voluntarily disclose diagnoses, treatment progress, or discharge summaries to employers, boards, or insurers without explicit, documented patient authorisation.
The revised Federal Act on Data Protection (FADP 2023), which entered into force on 1 September 2023, introduced stricter requirements around the processing of sensitive personal data. Health data is explicitly classified as sensitive under Article 5 of the new FADP. Institutions handling coordination files — including non-clinical intermediaries — must process such data under defined security and access controls. For families engaging a coordination platform to manage the admission, this means that any file containing diagnostic references, treatment correspondence, or institutional assessments must be handled under data processing agreements that comply with Swiss data protection standards.
In publicly listed companies or regulated financial institutions, the question of whether a senior executive's treatment admission constitutes a material fact subject to disclosure obligations is a recurring concern. Swiss financial market law (FINMASA) and relevant stock exchange regulations impose disclosure requirements when information is price-sensitive. Health conditions, by themselves, are not automatically disclosable. However, the capacity to perform key governance functions during a treatment period may be a relevant factor depending on the institution's internal policies, shareholder agreements, or employment contracts.
Families and legal advisors should review whether the executive's role carries statutory obligations — such as signatory authority, board quorum requirements, or regulated function notifications — that could create indirect disclosure pressure. This review is best completed before admission, not after a treatment file has been created. Coordination frameworks that separate the administrative admission record from the clinical treatment record provide an additional structural layer of protection, ensuring that institutional correspondence produced during coordination does not inadvertently constitute a medical record under Swiss law.
Private Swiss institutions routinely operate with multi-layered confidentiality protocols for executive admissions. At the coordination level, this typically involves limiting the flow of information to a defined set of authorised recipients — often a personal physician, a trusted legal advisor, and one designated family contact. Written consent protocols, produced at the point of intake, specify what may be shared, with whom, and under what conditions. These protocols are governed by both the institution's internal policies and by the FADP 2023 requirements applicable to all Swiss data processors.
Non-clinical coordination intermediaries play a specific role in this architecture. Their function is to manage logistical, administrative, and communication processes without generating clinical records. This distinction matters legally: correspondence from a coordination platform describing placement options, timeline management, and family communication protocols falls outside the scope of Article 321 CP and is not treated as medical data under the FADP. Families who understand this distinction can structure their engagement accordingly, limiting the volume of sensitive health information that circulates outside the direct clinical channel.
Families coordinating executive admissions should request a written confidentiality governance document from any institution under consideration. This document should specify who within the institution has access to the treatment file, how external communications are authorised, what happens to records on discharge, and how the institution responds to third-party requests for information. Institutions that cannot produce this document, or that treat it as a standard afterthought, may not be adequately equipped for the legal complexity of C-suite treatment files.
Legal advisors accompanying families through this process should distinguish between pre-admission planning — which can proceed with minimal information transfer — and the post-admission coordination phase, where clinical data begins to exist. Structuring the admission sequence so that legal review is completed before clinical records are generated is the most effective way to ensure that the governance framework is robust before it is tested.
Single-client format means that the entire clinical team — psychiatrist, psychologist, therapist, nursing staff, and support personnel — is assigned to one individual client. This format eliminates group interactions, provides maximum scheduling flexibility, and allows fully individualised therapeutic content. The clinical facility operates as a private residence, with no other patients present. This format represents the highest level of privacy and therapeutic individualisation available in residential addiction treatment.
Swiss single-client institutions implement admission processes designed for individuals in governance-sensitive positions: initial contact through secure, encrypted channels; preliminary assessment conducted under confidentiality agreements; alias registration for all institutional records; private transport from airport to facility; no shared spaces or interactions with other individuals; and dedicated secure communication systems for any necessary professional obligations during treatment.
Single-client residential facilities provide encrypted communication infrastructure including secure Wi-Fi networks, encrypted email and messaging platforms, dedicated phone lines, and private office space. Communication systems are designed to support limited professional engagement while maintaining complete separation from the treatment environment when needed. All digital infrastructure operates within Swiss data protection frameworks.
Single-client residential treatment programmes typically range from four to twelve weeks. The individualised format allows intensive therapeutic engagement — often multiple individual sessions daily — which may enable compressed treatment timelines compared to standard programmes. However, programme duration is determined by clinical progress and individual needs as assessed by the treating medical director.
Single-client residential treatment in Switzerland typically ranges from CHF 50,000 to CHF 150,000 per month, reflecting the exclusively individualised staffing, private facility, and comprehensive service provision. Pricing depends on clinical complexity, programme duration, and institutional resources. Detailed cost estimates are provided by the treating institution following preliminary assessment.
Single-client programmes operate under the same Swiss regulatory framework and clinical governance standards as larger institutions. Licensed Swiss medical directors — board-certified in psychiatry and addiction medicine — lead clinical teams. Treatment protocols follow evidence-based standards with clinical supervision and documentation requirements equivalent to those in multi-patient settings. Cantonal health authorities maintain oversight of all licensed treatment facilities regardless of patient volume.
SwissAtlas facilitates coordination for individuals requiring the highest level of privacy: confidential initial processing through secure channels, discreet documentation handling, introductions to institutions offering single-client format, private transport coordination, and aftercare planning. SwissAtlas has no involvement in clinical decisions — all treatment planning and medical management are conducted by the treating institution's clinical team.
Related pages: Addiction Treatment Overview · Executive Rehab · Alcohol Rehab · Healthcare · Private Coordination · Process · Coordination Framework
Confidential access to private medical care in Switzerland.
SwissAtlas operates at the intersection of discretion, structure, and access. Unlike traditional intermediaries, we do not promote specific clinics or treatments. Our role is to provide a neutral, structured, and confidential coordination layer for international patients navigating complex medical situations. This approach allows families to move forward with clarity, without pressure, and without exposure.
SwissAtlas is designed for: international families seeking discretion; patients requiring fast and structured access; situations where clarity and confidentiality are essential.
No medical advice. No pressure. Only structured coordination.
SwissAtlas is a non-medical coordination platform registered in Switzerland. SwissAtlas does not provide medical advice, clinical assessment, diagnostic services, treatment recommendations, or any form of healthcare service. All information presented on this page is provided for general educational and informational purposes only and does not constitute medical advice or a substitute for professional medical consultation.
SwissAtlas does not evaluate, rank, endorse, recommend, or express any preference regarding any medical institution, healthcare provider, clinical programme, or treatment modality. The coordination services provided by SwissAtlas are exclusively non-clinical and administrative in nature.
All medical decisions are the sole responsibility of the patient and their chosen medical professionals. Patients are strongly encouraged to seek independent medical advice from qualified healthcare professionals before making any healthcare decisions.
For the complete strategic framework, review medical travel in Switzerland, treatment in Switzerland for international patients, and private healthcare Switzerland.